A rare rosuvastatin-induced urticaria in a high-risk cardiovascular patient: A case report

Statins are widely used lipid-lowering agents essential for the prevention and management of cardiovascular diseases. Despite their proven efficacy and safety, rare adverse drug reactions (ADRs), such as allergic skin reactions, can occur. This case report describes a 54-year-old male with ischemic heart disease, hypertension, and type 2 diabetes mellitus, who developed pruritic, red-pigmented skin lesions characteristic of urticaria within 10 days of starting rosuvastatin 40 mg daily. The symptoms resolved after discontinuation of the drug and administration of symptomatic treatment with cetirizine and calamine lotion. The likelihood of rosuvastatin causing the urticaria was assessed using the Naranjo Adverse Drug Reaction Probability Scale, which indicated a probable relationship. Although statins are generally well-tolerated, rare hypersensitivity reactions may occur due to immune-mediated mechanisms or mast cell activation. Early recognition and withdrawal of the offending agent are crucial for swift symptom resolution and prevention of further complications. In patients requiring continued lipid-lowering therapy, alternative agents such as pravastatin may be considered. This case highlights the importance of post-marketing surveillance in identifying rare ADRs, ensuring pharmacovigilance, and improving patient care. Increased awareness among clinicians is essential for timely detection and management of uncommon drug-related reactions to enhance treatment outcomes.